Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-20 02:02 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses, and New Cures

Sunday, July 20, 2026 | Edition #366

⚡ TL;DR

The Ebola Bundibugyo virus disease outbreak in DRC and Uganda has now reached 2,124 confirmed cases and 828 deaths as of July 15, marking the deadliest filovirus event in years and dominating global health attention. Mood: urgent but cautiously active — the PARTNERS treatment trial is enrolling patients, a WHO-listed diagnostic test is deployed, and dementia prevention guidelines offer a rare piece of good news. [1] [2] [3]

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS DISEASE - DRC AND UGANDA (ACTIVE PHEIC)

  • As of July 15, 2026, a cumulative 2,124 confirmed cases and 828 deaths have been reported from the Democratic Republic of the Congo, with cross-border transmission ongoing into Uganda. [1]
  • The outbreak was first detected in Mongbwalu Health Zone, Ituri Province, DRC, on May 5, 2026; Bundibugyo virus was laboratory-confirmed by the Institut national de recherche biomédicale (INRB) on May 14. [4]
  • WHO declared this event a Public Health Emergency of International Concern (PHEIC) on May 22, 2026, after the first IHR Emergency Committee meeting; it does not yet meet the criteria for pandemic emergency. [5]
  • Africa CDC and WHO launched a joint continental preparedness and response plan on June 5, 2026, seeking to raise US$518 million to support African country responses. [6]
  • WHO issued its first comprehensive clinical management guidelines covering all filovirus types, including all Ebola strains and Marburg, on June 17, 2026. [7]
  • On July 2, 2026, WHO added the first-ever molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing, enabling rapid genetic detection from blood samples. [8]
  • The PARTNERS clinical trial opened patient enrolment in DRC on July 2, 2026, to identify the first effective treatments specifically for Bundibugyo virus disease. [2]
  • CDC mobilized an international Ebola response beginning May 17, 2026, and expanded enhanced airport screening from Washington-Dulles to Atlanta's Hartsfield-Jackson by May 23. [9] [10]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY)

  • The Andes hantavirus (ANDV) outbreak linked to cruise ship M/V Hondius was first notified to WHO on May 2, 2026; the ship was carrying 147 passengers and crew at detection.
  • As of the fifth WHO Disease Outbreak News report (July 2, 2026), additional confirmed cases had accumulated across multiple countries following disembarkation of passengers.
  • Andes hantavirus causes severe acute respiratory illness; person-to-person transmission is documented for this strain, distinguishing it from most other hantavirus species.
  • CDC has been providing regular response updates through June 24, 2026, and monitors U.S. travelers who were aboard.

NIPAH VIRUS - INDIA (KERALA)

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district; the adult male developed symptoms on May 30 and was hospitalized June 10.
  • This follows a separate Nipah case confirmed in Rajshahi Division, Bangladesh, reported to WHO on February 6, 2026; that patient developed fever and neurological symptoms on January 21.
  • Both cases highlight continued endemic risk of NiV spillover from fruit bats (Pteropus spp.) in South Asia.

AVIAN INFLUENZA A(H9N2) - ITALY

  • WHO was notified on March 21, 2026, of an H9N2 human case in an adult male returning to Italy from Senegal; next-generation sequencing confirmed influenza A(H9N2).
  • H9N2 is a low-pathogenic avian influenza virus; human cases are rare but signal ongoing zoonotic spillover risk from poultry.

MEASLES - BANGLADESH

  • Bangladesh reported 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts, spanning all eight divisions, as notified to WHO on April 4, 2026.
  • The WHO-UNICEF 2025 immunization coverage data (released July 15, 2026) show only 85% of infants globally completed the full DTP three-dose series, underscoring gaps that leave populations measles-vulnerable.

YELLOW FEVER - GLOBAL

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission activity in the Americas persisted into 2026 following a case surge in 2025.

MPOX - RECOMBINANT STRAIN

  • WHO documented two cases of a novel recombinant monkeypox virus (MPXV) strain combining genomic elements of clade Ib and clade IIb, reported in a February 14, 2026 Disease Outbreak News entry.
  • Recombination can occur when two strains co-infect a single host; the public health implications of this genomic mixing are under active assessment.

CYCLOSPORIASIS - ACTIVE U.S. RESPONSE

  • CDC held a Cyclosporiasis response update on July 14, 2026, indicating an ongoing domestic investigation into Cyclospora infections.

WEST NILE VIRUS - EARLY U.S. SEASON

  • CDC warned on July 1, 2026, that the 2026 West Nile season is showing record early-season cases, urging mosquito bite prevention over the Independence Day holiday weekend.

🧬 LONGEVITY & AGING

WHO DEMENTIA PREVENTION GUIDELINES

  • WHO released updated guidelines on July 15, 2026, concluding that up to 45% of dementia risk could be prevented or delayed through evidence-based interventions across the life course. [3]
  • The guidelines provide countries with actionable, population-level recommendations targeting modifiable risk factors such as physical inactivity, hypertension, diabetes, smoking, and social isolation. [3]

DELIRIUM AS A BRIDGE FROM INFECTION TO DEMENTIA

  • Two linked commentaries in Lancet Healthy Longevity (Sipilä and Kivimäki; Penfold, Jiwaji, and MacLullich) propose that delirium following severe infection may be the mechanistic "missing link" connecting acute illness to long-term cognitive decline and dementia.
  • The hypothesis suggests that infection-triggered neuroinflammation manifests as delirium acutely and drives neurodegeneration chronically, opening potential intervention windows.

PREPARING FOR A DEMENTIA PREVENTION ERA

  • Beeri and Gu, writing in Lancet Healthy Longevity, call for practical dementia prevention strategies suited to real-world health systems, including addressing social determinants and health equity alongside biomedical factors.

NAD+ RESTORATION AND AGED BONE REPAIR

  • A study published in Bioactive Materials (Jiang et al., June 27, 2026) describes a senescent metabolism-modulating hierarchical scaffold that restores NAD+ homeostasis and redox balance in aged bone tissue.
  • NAD+ depletion is a hallmark of cellular senescence; scaffolds that reverse this may offer a pathway to improved fracture healing in elderly patients.

KAEMPFEROL FROM MORINGA AND LONGEVITY IN DROSOPHILA

  • Iorjiim et al. (Toxicology Reports, June 25, 2026) found that kaempferol derived from Moringa oleifera increased lifespan and reduced efavirenz-induced functional senescence in Drosophila melanogaster.
  • Efavirenz is an antiretroviral drug; the findings suggest kaempferol may counteract drug-accelerated aging mechanisms, though results require translation to mammalian models.

COLLAGEN XVII AND PHOTOAGING IN SKIN STEM CELLS

  • Wang et al. (Annals of Medicine, July 16, 2026) reported that recombinant human collagen XVII protects epidermal stem cells from blue-light-induced photoaging by downregulating the Notch signaling pathway.
  • Epidermal stem cell preservation is central to skin regeneration and healthy aging; Notch suppression reduced markers of cellular senescence in the exposed cells.

EMERIN, TAU, AND NEURODEGENERATION

  • Sohn et al. (Nucleus, July 7, 2026) demonstrated that the mechanically sensitive nuclear envelope protein emerin links nuclear mechanotransduction to tau-induced cytoskeletal remodeling in neurons.
  • This pathway is relevant to Alzheimer's disease and other tauopathies, suggesting that nuclear mechanical signaling may be an upstream driver of tau pathology.

HYPERTENSION AND FRAILTY IN OLDER ADULTS

  • A letter to the editor in Blood Pressure (Goyal, Kalra, and Nagpal, July 7, 2026) highlighted evidence from the Longitudinal Ageing Study in India linking hypertension to accelerated frailty in middle-aged and older adults.
  • Frailty is a key longevity-limiting syndrome; the India cohort data expand understanding of hypertension's role beyond cardiovascular risk to whole-body aging trajectories.

PHYSICAL ACTIVITY RESTRICTIONS AND CEREBROVASCULAR MORTALITY - JAPAN

  • Kimura (Dialogues in Health, June 11, 2026) analyzed 47 Japanese prefectures from 2013 to 2022, finding that structural physical activity restrictions were associated with higher cerebrovascular and diabetes mortality and increased long-term care intensity, with a COVID-19 counterfactual analysis strengthening causal inference.

CANCER CASES PROJECTED TO NEARLY DOUBLE BY 2050

  • A WHO report released July 8, 2026, projects new cancer cases will rise from 20.6 million annually now to nearly double by 2050, with close to 10 million deaths per year currently — over 26,000 per day.
  • Population aging and growth are primary drivers; the report calls for urgent expansion of prevention, early detection, and treatment infrastructure worldwide.

💊 NEW CURES & APPROVALS

ENLICITIDE (ENLICITIDE CHLORIDE) - MERCK SHARP AND DOHME LLC

  • Merck Sharp and Dohme LLC received an original FDA application approval for ENLICITIDE (enlicitide chloride), NDA220848, a new molecular entity.
  • Enlicitide is an oral small-molecule PCSK9 inhibitor in development for LDL cholesterol lowering; this entry reflects an original application action at FDA.

REVTORPYK (GEDATOLISIB) - CELCUITY INC.

  • Celcuity Inc. received an original FDA application approval for REVTORPYK (gedatolisib), NDA219908; gedatolisib is a pan-PI3K/mTOR inhibitor being evaluated in hormone receptor-positive breast cancer.

RETEVMO (SELPERCATINIB) - ELI LILLY AND CO.

  • Eli Lilly and Co. received supplemental FDA application actions on two Retevmo (selpercatinib) applications (NDA213246 and NDA218160); selpercatinib is a RET kinase inhibitor approved for RET-altered non-small cell lung cancer, thyroid cancer, and other RET-fusion solid tumors.

REPATHA (EVOLOCUMAB) - AMGEN INC.

  • Amgen Inc. received a supplemental FDA application action on Repatha (evolocumab), BLA125522; evolocumab is an anti-PCSK9 monoclonal antibody indicated for LDL lowering and cardiovascular risk reduction.

STELARA (USTEKINUMAB) - CENTOCOR ORTHO BIOTECH INC.

  • A supplemental FDA application action was recorded for Stelara (ustekinumab), BLA125261; ustekinumab is an IL-12/IL-23 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

AFATINIB DIMALEATE GENERICS - HETERO LABS AND APOTEX

  • Hetero Labs Ltd V (ANDA210750) and Apotex (ANDA210725) each received original ANDA approvals for afatinib dimaleate, a generic form of the EGFR inhibitor used in EGFR-mutant non-small cell lung cancer.

🧪 CLINICAL TRIALS

PARTNERS TRIAL - BUNDIBUGYO VIRUS DISEASE TREATMENTS

  • The PARTNERS clinical trial opened patient enrolment on July 2, 2026, in the DRC, representing the first-ever systematic effort to identify effective therapeutics specifically for Ebola disease caused by Bundibugyo virus. [2]
  • WHO is coordinating the trial; no approved treatment currently exists for Bundibugyo virus disease, which has a historically high case fatality ratio. [2]

DOCETAXEL + SX-682 IN HEAD AND NECK AND PROSTATE CANCER (NCT07667400)

  • A new trial registered July 17, 2026, combines docetaxel chemotherapy with SX-682 (a CXCR1/2 inhibitor targeting myeloid-derived suppressor cells) in recurrent/metastatic head and neck squamous cell carcinoma, salivary gland carcinoma, and advanced prostate cancer.
  • Head and neck cancers account for approximately 5% of global cancers; survival below 50% for metastatic disease makes new combinations an urgent priority.

IL-15 SUPERAGONIST N-803 WITH VACCINE ETBX-071 IN BIOCHEMICALLY RECURRENT PROSTATE CANCER (NCT07686380)

  • A trial registered July 17, 2026, tests N-803 (an IL-15 superagonist) alone or combined with ETBX-071 vaccine in men with biochemically recurrent prostate cancer after stereotactic body radiation therapy; biochemically recurrent disease affects 30,000 to 50,000 men annually in the U.S.

FLUOROCELLOBIOSE [18F]FCB PET IMAGING FOR INVASIVE MOLD INFECTIONS (NCT07704333)

  • A pharmacokinetics trial registered July 17, 2026, tests the radiotracer [18F]-fluorocellobiose in healthy volunteers and patients with invasive mold infections, with the goal of enabling fungal infection detection by PET imaging; roughly 3.8 million people die with fungal infections annually.

NUTRITIONAL MANAGEMENT OF LONG-COVID COGNITIVE SYMPTOMS (NCT05705648)

  • An ongoing trial studies the natural course of brain fog in adults aged 22-50 with long-COVID and tests whether supplemental dietary oil can improve cognitive outcomes.

TRANSPERINEAL VERSUS TRANSRECTAL PROSTATE BIOPSY (NCT07710807)

  • A randomized controlled trial registered July 17, 2026, compares transperineal and transrectal cognitive fusion prostate biopsy in patients aged 50-75 with PI-RADS 3-5 lesions on mpMRI, relevant to early prostate cancer detection in an aging male population.

📢 PUBLIC HEALTH

FIFA WORLD CUP 2026 - CDC PUBLIC HEALTH RESPONSE

  • CDC issued statements on July 19, 2026, covering its public health readiness and response for the FIFA World Cup 2026, which brought 48 teams and millions of fans to 16 North American cities.
  • The response included activation alongside Ebola outbreak protocols, given concurrent disease threats during the tournament period.

CYCLOSPORIASIS RESPONSE ONGOING

  • CDC held a Cyclosporiasis response update briefing on July 14, 2026; Cyclospora cayetanensis continues to cause seasonal foodborne illness outbreaks, historically linked to fresh produce.

WEST NILE VIRUS EARLY SEASON WARNING

  • CDC flagged record-high early West Nile virus ER visit data on July 1, 2026, advising Americans to use EPA-registered repellents and eliminate standing water.

E. COLI OUTBREAK LINKED TO FROZEN BLUEBERRIES

  • CDC issued a food safety alert on July 7, 2026, warning consumers not to eat recalled frozen blueberries linked to a multistate E. coli outbreak.

DECLINE IN HEALTHCARE-ASSOCIATED INFECTIONS

  • CDC data released July 15, 2026, show fewer hospital-acquired infections in 2023, reflecting improved patient safety practices across U.S. healthcare facilities.

WHO DEMENTIA RISK - 45% PREVENTABLE

  • WHO's July 15, 2026 guidelines reinforce that lifestyle and vascular risk factor management throughout life — not just in old age — are the most powerful tools available today against dementia. [3]

NEW WORLD SCREWWORM EMERGENCY OPERATIONS

  • CDC activated its Emergency Operations Center for a New World Screwworm (Cochliomyia hominivorax) response on June 12, 2026, addressing the flesh-eating parasite's northward spread toward the U.S.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Patient enrolment begins in a scientific trial to identify the… — WHO News
  3. New WHO guidelines: up to 45% of dementia risk could be preven… — WHO News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  6. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  7. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  8. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  9. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  10. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260720-02-v33 · 2026-07-20 02:02 UTC · pulse.uzylab.com

Read next